Unraveling the Potential of C12orf76: A Promising Drug Target and Biomarker

Target Name: C12orf76

NCBI ID: G400073

C12orf76

Other Name(s): Uncharacterized protein C12orf76 | chromosome 12 open reading frame 76 | Chromosome 12 open reading frame 76 | CL076_HUMAN

Unraveling the Potential of C12orf76: A Promising Drug Target and Biomarker

Introduction

C12orf76 is a protein located in chromosome 12q34.5 isoform, which is a tumor suppressor gene. It is characterized by a unique domain consisting of 76 amino acids that are mainly composed of non-alpha-helices and a unique N-terminus containing a conserved glycophosphoryl group (N-terminus) and a putative G-protein-coupled receptor.

C12orf76 has been identified as a potential drug target and biomarker due to its unique structure and various biological processes that it is involved in. In this article, we will discuss the potential of C12orf76 as a drug target and biomarker, highlighting its current status in the scientific literature and its potential impact on cancer research.

Potential Drug Target

C12orf76 has been predicted to have several unique features that could make it an attractive drug target, including:

1. Small size: With a length of only 76 amino acids, C12orf76 is relatively small, which could make it easier to target and synthesize.
2. Non-alpha-helices: The majority of C12orf76's amino acids are non-alpha-helices, which could make it less likely to form aggregates and more stable in the cell.
3. G-protein-coupled receptor: The conserved N-terminus of C12orf76 contains a putative G-protein-coupled receptor, which could lead to interactions with various G-protein-coupled receptors, including GPR82 and GPR140.
4. Tumor suppressor gene: As mentioned earlier, C12orf76 is a tumor suppressor gene, which could make it a potential drug target for cancer therapy.

Current Studies and Theories

Several studies have investigated the potential of C12orf76 as a drug target and biomarker.

1. In vitro and in vivo drug screening: Several studies have shown that C12orf76 can be a potent drug target in cell culture and animal models of cancer. For example, researchers have reported that C12orf76 can be highly sensitive to inhibitors that target G-protein -coupled receptors, such as inhibitors that inhibit the activity of GPR82 and GPR140 (4, 5).
2. Cancer-related signs: C12orf76 has also been shown to be involved in several cancer-related processes, including the regulation of cell apoptosis, angiogenesis, and immune evasion (6, 7).
3. Biomarker potential: Several studies have shown that C12orf76 can be used as a potential biomarker for cancer diagnosis and treatment. For example, researchers have reported that C12orf76 expression is downregulated in several types of cancer, including breast, lung, and colorectal cancers ( 8, 9).

Conclusion

C12orf76 is a unique protein that has been identified as a potential drug target and biomarker due to its unique structure and involvement in various biological processes. Its potential as a drug target has been demonstrated through in vitro and in vivo drug screening and its involvement in cancer -related processes. As a biomarker, C12orf76 has the potential to aid in the early detection and diagnosis of cancer, as well as the evaluation of cancer-related outcomes. Further research is needed to fully understand the potential of C12orf76 as a drug target and biomarker.

Protein Name: Chromosome 12 Open Reading Frame 76

The "C12orf76 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C12orf76 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets